New SEREX Antigens, Molecular Target to Diagnosis and Treatment for Esophageal Cancer

为了寻找新的食管鳞状细胞癌（SCC）血清标志物，采用重组cDNA表达克隆技术（SEREX）对抗原进行了血清学鉴定。用食管癌细胞株（T.Tn） mRNA制备的λZAPII噬菌体cDNA文库感染大肠杆菌，筛选iptg诱导的cDNA产物与食管鳞状细胞癌患者同种异体血清抗体的相互作用。我们鉴定出TROP-2、GLUT-1/SLC2A1、TRIM21、myomegalin作为食管SCC的新的SEREX抗原。Western blotting分析显示，20 - 47%的患者血清中存在这些SEREX抗原的抗抗体，但在健康对照中没有。虽然血清SEREX-Abs的存在与相关患者的任何临床病理特征无关，但多因素分析表明，s-myomegalin-Abs的存在与良好的预后显著相关。此外，s-TROP-2-Abs与肿瘤大小相关。由于血清中SEREX抗原抗体与其他常规肿瘤标志物无相关性，因此血清标志物可作为食管鳞状细胞癌新的肿瘤标志物。

In order to identify new serum markers of esophageal squamous cell carcinoma (SCC), we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX). E.coli was infected with λZAPII phage cDNA library prepared from mRNA of an esophageal cancer cell line (T.Tn), and IPTG-induced cDNA products were screened for interaction with antibodies in allogeneic sera of patients with esophageal SCC. We identified TROP-2, GLUT-1/SLC2A1, TRIM21, myomegalin, as new SEREX antigens for esophageal SCC. Western blotting analysis revealed that serum anti-antibodies for these SEREX antigens were present in 20 to 47% of patients but not in healthy controls. Although the presence of serum SEREX-Abs were not related to any of clinicopathological features of the patients concerned, multivariate analysis indicated that presence of s-myomegalin-Abs was significantly associated with favorable prognosis. Moreover, s-TROP-2-Abs was associated with tumor size. Because there serum antibodies against SEREX antigens were not associated with other conventional tumor markers, there serum markers were useful as a new tumor markers for esophageal SCC.